Alivus Life Sciences share news and announcements
NSE: ALIVUSBSE: 543322Pharmaceuticals & BiotechnologySmall Cap
Formerly Glenmark Life Sciences
Last close ₹1,250.60down ₹18.40 (1.45%)BSE ₹1,247.30
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,269.00.
52-week range of traded prices to 23 Oct 2026
₹819.00Low, 22 Jan 2026₹1,493.80High, 31 Aug 2026
- Next results date: the board meets on 29 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹15,354 Cr502nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 30 Jul 2026
- 25.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 14 May 2026
- 4.6
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.40%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 30 Jul 2026
- 19.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 30 Jul 2026
- 22.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 14 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 87,23655.9% delivered
Next board meeting and results date
As the company gave notice to the exchange.Alivus Life Sciences quarterly results
Oct29Thu
The board meets on 29 Oct 2026 to consider financial results
Notice filed 21 Oct 2026
Alivus Life Sciences annual reports, presentations and earnings calls
The company's own documents, latest first.Alivus Life Sciences financials, year by year
Annual reports5
- Annual report, year to Mar 2026 (opens in a new tab)11 Aug 2026
- Annual report, year to Mar 2025 (opens in a new tab)12 Aug 2025
- Annual report, year to Mar 2024 (opens in a new tab)2 Sep 2024
- Annual report, year to Mar 2023 (opens in a new tab)1 Sep 2023, a zip file
- Annual report, year to Mar 2022 (opens in a new tab)30 Aug 2022, a zip file
Investor presentations23
- Investor Presentation (opens in a new tab)30 Jul 2026
- Investor Presentation (opens in a new tab)14 May 2026
- Investor Presentation (opens in a new tab)22 Jan 2026
- Investor Presentation (opens in a new tab)6 Nov 2025
- Investor Presentation (opens in a new tab)1 Aug 2025
18 earlier presentations
- Investor Presentation (opens in a new tab)15 May 2025
- Investor Presentation (opens in a new tab)23 Jan 2025
- Investor Presentation (opens in a new tab)24 Oct 2024
- Investor Presentation (opens in a new tab)25 Jul 2024
- Investor Presentation (opens in a new tab)25 Apr 2024
- Investor Presentation (opens in a new tab)11 Mar 2024
- Investor Presentation (opens in a new tab)23 Jan 2024
- Investor Presentation (opens in a new tab)20 Oct 2023
- Investor Presentation (opens in a new tab)21 Jul 2023
- Investor Presentation (opens in a new tab)27 Apr 2023
- Investor Presentation (opens in a new tab)27 Jan 2023
- Investor Presentation (opens in a new tab)17 Nov 2022
- Further to our communication dated November 11, 2022, attached is a copy of the presentation to be made at Glenmark Life Sciences Limited - Investor Day 2022 which is scheduled today at 15:45 IST in Mumbai.Kindly take the same on record and acknowledge receipt. (opens in a new tab)17 Nov 2022
- Investor Presentation (opens in a new tab)21 Oct 2022
- We are enclosing the investor presentation. (opens in a new tab)4 Aug 2022
- We are enclosing the investor presentation. (opens in a new tab)20 Apr 2022
- Investor Presentation (opens in a new tab)8 Feb 2022
- Investor Presentation (opens in a new tab)10 Nov 2021
Earnings calls32
- Transcript of earnings call held on July 31, 2026. (opens in a new tab)7 Aug 2026
- Link of Recording (opens in a new tab)31 Jul 2026
- Transcript of Earnings Call. (opens in a new tab)21 May 2026
- Link of Earnings Call Recording (opens in a new tab)15 May 2026
- Transcript of Earnings Call (opens in a new tab)30 Jan 2026
27 earlier call documents
- Link of Recording of Earnings Call (opens in a new tab)22 Jan 2026
- Transcript (opens in a new tab)13 Nov 2025
- Weblink of Recording of Earnings Call Q2 FY2026. (opens in a new tab)7 Nov 2025
- Transcript (opens in a new tab)8 Aug 2025
- Link of Recording (opens in a new tab)2 Aug 2025
- Transcript (opens in a new tab)23 May 2025
- Link of Recording (opens in a new tab)16 May 2025
- Transcript (opens in a new tab)30 Jan 2025
- Link of Recording (opens in a new tab)23 Jan 2025
- Transcript (opens in a new tab)31 Oct 2024
- Link of Recording (opens in a new tab)25 Oct 2024
- Transcript (opens in a new tab)2 Aug 2024
- Link of Recording (opens in a new tab)26 Jul 2024
- Transcript (opens in a new tab)3 May 2024
- Link of Recording (opens in a new tab)26 Apr 2024
- Transcript (opens in a new tab)31 Jan 2024
- Link of Recording (opens in a new tab)24 Jan 2024
- Transcript (opens in a new tab)25 Oct 2023
- Transcript (opens in a new tab)24 Jul 2023
- Link of Recording (opens in a new tab)21 Jul 2023
- Transcript (opens in a new tab)2 May 2023
- Link of Recording (opens in a new tab)28 Apr 2023
- Transcript (opens in a new tab)1 Feb 2023
- Link of Recording (opens in a new tab)28 Jan 2023
- Pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the transcript of the Earnings call held on Friday, October 21, 2022 for the quarter and half year ended September 30, 2022 is available on the Company's website at:https://www.glenmarklifesciences.com/pdf/Transcript%20of%20Earnings%20Concall%20Q2%20FY2022-23.pdfThe said transcript is also attached. (opens in a new tab)27 Oct 2022
- Pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the transcript of the Earnings call held on Friday, 5th August, 2022 for the quarter ended June 30, 2022 is available on the Company's website at:https://www.glenmarklifesciences.com/pdf/Transcript%20of%20Earnings%20Concall%20Q1%20FY2022-23.pdf (opens in a new tab)8 Aug 2022
- Recording of Analysts/Institutional Investor Meet/Con. Call (opens in a new tab)5 Aug 2022
Alivus Life Sciences share news and announcements
279 announcements, routine notices left out, newest first. Page 1 of 6.
Oct 2026
22 Oct · Analysts
7 Oct · General Updates
Sep 2026
16 Sep · General Updates
11 Sep · Analysts
7 Sep · Analysts
5 Sep · Analysts
Aug 2026
25 Aug · Analysts
13 Aug · Analysts
7 Aug · Analysts
7 Aug · Analysts
Jul 2026
23 Jul · Analysts
Jun 2026
23 Jun · Analysts
4 Jun · Analysts
May 2026
20 May · Analysts
19 May · Analysts
14 May · Disclosure
8 May · Analysts
Mar 2026
Feb 2026
25 Feb · Updates
2 Feb · Analysts
Jan 2026
21 Jan · Disclosure
15 Jan · Analysts
Dec 2025
24 Dec · Analysts
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts).
- 31 Jul 2026Resultsup 5.87%+5.4 pts vs Nifty 500market median −0.7% · five sessions +20.9% (+19.3 pts vs Nifty 500) · volume 2.8× usual · delivery −26.1 pts against usual · The announcement (opens in a new tab)
- 15 May 2026Resultsdown 1.83%−1.5 pts vs Nifty 500market median −0.7% · five sessions −0.7% (−0.7 pts vs Nifty 500) · volume 1.8× usual · delivery +7.1 pts against usual · The announcement (opens in a new tab)
- 7 Nov 2025Resultsup 2.76%+2.7 pts vs Nifty 500market median −0.7% · five sessions +1.5% (+0.2 pts vs Nifty 500) · volume 1.6× usual · delivery −11.8 pts against usual · The announcement (opens in a new tab)
- 17 Sep 2025Credit ratingup 0.26%−0.1 pts vs Nifty 500market median 0.0% · five sessions +5.0% (+5.2 pts vs Nifty 500) · volume 1.5× usual · delivery +17.2 pts against usual · The announcement (opens in a new tab)
- 4 Aug 2025Resultsdown 3.49%−4.3 pts vs Nifty 500market median −0.7% · five sessions −6.6% (−5.6 pts vs Nifty 500) · volume 1.6× usual · delivery −7.7 pts against usual · The announcement (opens in a new tab)
- 16 May 2025Resultsdown 5.26%−5.6 pts vs Nifty 500market median −0.7% · five sessions −8.5% (−7.6 pts vs Nifty 500) · volume 2.1× usual · delivery −10.3 pts against usual · The announcement (opens in a new tab)
- 16 May 2025Dividenddown 5.26%−5.6 pts vs Nifty 500market median 0.0% · five sessions −8.5% (−7.6 pts vs Nifty 500) · volume 2.1× usual · delivery −10.3 pts against usual · The announcement (opens in a new tab)
- 20 Jun 2024Credit ratingdown 0.70%−1.1 pts vs Nifty 500market median 0.0% · five sessions −0.4% (−1.3 pts vs Nifty 500) · volume 0.3× usual · The announcement (opens in a new tab)
- 24 Apr 2024Board or managers changedup 0.03%−0.3 pts vs Nifty 500market median 0.0% · five sessions +0.3% (−1.3 pts vs Nifty 500) · volume 0.3× usual · The announcement (opens in a new tab)
- 22 Apr 2024Board or managers changedup 4.60%+3.7 pts vs Nifty 500market median 0.0% · five sessions +1.5% (−0.7 pts vs Nifty 500) · volume 1.4× usual · The announcement (opens in a new tab)
8 earlier announcements
- 7 Mar 2024Board or managers changedup 3.95%+3.7 pts vs Nifty 500market median 0.0% · five sessions −1.9% (+0.4 pts vs Nifty 500) · volume 1.3× usual · The announcement (opens in a new tab)
- 10 Oct 2023Dividendup 1.57%+0.5 pts vs Nifty 500market median 0.0% · five sessions +7.1% (+5.6 pts vs Nifty 500) · volume 1.2× usual · The announcement (opens in a new tab)
- 5 Oct 2023Credit ratingup 0.12%−0.3 pts vs Nifty 500market median 0.0% · five sessions +2.8% (+1.1 pts vs Nifty 500) · volume 2.8× usual · The announcement (opens in a new tab)
- 25 Sep 2023Credit ratingdown 2.33%−2.4 pts vs Nifty 500market median 0.0% · five sessions −4.2% (−4.4 pts vs Nifty 500) · volume 1.7× usual · The announcement (opens in a new tab)
- 17 Mar 2023Dividendup 5.04%+4.4 pts vs Nifty 500market median 0.0% · five sessions +6.8% (+6.3 pts vs Nifty 500) · volume 3.2× usual · The announcement (opens in a new tab)
- 21 Oct 2022Board or managers changeddown 0.22%0.0 pts vs Nifty 500market median 0.0% · five sessions +2.4% (+1.5 pts vs Nifty 500) · volume 0.2× usual · The announcement (opens in a new tab)
- 21 Apr 2022Board or managers changeddown 0.13%−1.5 pts vs Nifty 500market median 0.0% · five sessions −0.9% (−0.3 pts vs Nifty 500) · volume 1.0× usual · The announcement (opens in a new tab)
- 8 Nov 2021Dividendup 0.62%−0.3 pts vs Nifty 500market median 0.0% · five sessions +2.4% (+1.1 pts vs Nifty 500) · volume 0.7× usual · The announcement (opens in a new tab)
Alivus Life Sciences results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.